Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum

Table 4

Patient demographics and serum creatinine, mesothelin, and MPF concentrations in patients with chronic kidney disease (CKD).

CKD stage	Number of cases; (number of females)	Mean age, years; (range)	Median eGFR^a; (mL/min/1.73 m²); (range)	Serum mesothelin; (nM)^b,d	Serum MPF; (ng/mL)^b,c,d
II	30 (12)	68 (25–95)	74 (62–89)	1.05±0.09	16.5±1.8
III	32 (16)	68 (42–91)	40 (30–59)	1.4±0.15^∗	32.1±2.86^∗∗∗
IV	30 (12)	64 (32–96)	22 (16–28)	2.4±0.19^∗∗∗	46.2±5.4^∗∗∗
V	29 (13)	66 (46–96)	12 (3–14)	2.8±0.29^∗∗∗	53.6±7.6^∗∗∗

aestimated glomerular filtration rate was calculated using the Modified Diet in Renal Disease (MDRD) Formula [27].
^bexponentiated mean of log transformed data plus/minus standard error of log transformed data *100.
^cMPF concentrations determined from Human MPF Assay (MBL).
^dsignificant difference between indicated cohorts and the Stage II CKD patient group (𝑛=30) as determined by Student’s 𝑡-test (* is 𝑃<0.05; *** is 𝑃<0.0001).